Erythrocyte disorder
MONDO:0044347A disease or disorder that involves the erythrocyte.
Also known as: disease of erythrocyte, disease or disorder of erythrocyte, disorder of erythrocyte, erythrocyte disease, erythrocyte disease or disorder, red blood cell disease, red blood cell disorder
564 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Early malaria vaccine trial halted – what we know
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tested a new vaccine against Plasmodium vivax malaria, given with an adjuvant to boost immune response. It involved 25 healthy adults in the UK to check safety and immune reactions. The study was terminated early, so full results are not available.
Phase: EARLY_PHASE1 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
-
Sickle cell transplant study halted after just one patient
Disease control TerminatedThis study tested a drug called siplizumab alongside a stem cell transplant for people with severe sickle cell disease. The goal was to see if it could prevent the body from rejecting the new cells and reduce a serious side effect called graft-versus-host disease. Only one person…
Phase: PHASE1, PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Sickle cell drug safety trial ends early
Disease control TerminatedThis study looked at the long-term safety of the drug osivelotor in people with sickle cell disease who had already taken it in an earlier trial. The goal was to track side effects and blood changes over time. However, the study was terminated early, so the full safety picture is…
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Sickle cell drug trial in kids halted early – but data may still help
Disease control TerminatedThis study tested a daily pill called voxelotor in children aged 2 to 14 with sickle cell disease who had slightly abnormal blood flow in the brain. The goal was to see if the drug could improve that blood flow and reduce stroke risk. The trial was stopped early, but the results …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cancer drug may tame sickle cell pain, early study hints
Disease control TerminatedThis small pilot study tested whether imatinib, a drug used for certain cancers, could reduce painful blockages in blood vessels (vaso-occlusive crises) in people with sickle cell anemia. Seven participants aged 18–25 took the drug for 6 months while researchers measured changes …
Phase: PHASE1, PHASE2 • Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Sickle cell drug candidate tested in first human trial – but study halted early
Disease control TerminatedThis was a first-in-human study testing a single dose of an experimental drug called GSK4172239D in 11 people with sickle cell disease. The main goals were to check safety and how the drug moves through the body. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can extra care after transplant help older patients live better?
Disease control TerminatedThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase: PHASE2, PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New malaria pill for tiny infants studied, but trial stopped early
Disease control TerminatedThis study tested a new, easy-to-dissolve malaria tablet in infants and newborns weighing less than 5 kg who had uncomplicated malaria. The goal was to see how the medicine worked in the body, how safe it was, and how well it treated the infection. The trial was stopped early aft…
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Sickle cell gene therapy trial halted after just 4 patients
Disease control TerminatedThis early-phase trial tested a gene-edited stem cell product called OTQ923 in 4 people with severe sickle cell disease. The goal was to boost fetal hemoglobin to reduce painful crises and other complications. The study was terminated early, so we have limited data on safety and …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Sickle cell drug oxbryta tracked in real life: what happened?
Disease control TerminatedThis study followed 265 people with sickle cell disease who were taking Oxbryta (voxelotor) as part of their normal care. Researchers wanted to see how the drug affected hemoglobin levels, sickle cell complications, and overall health over up to 5 years. The study was observation…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Sickle cell drug inclacumab safety checked in long-term study
Disease control TerminatedThis study looks at the long-term safety of inclacumab in people with sickle cell disease who have already taken the drug in a previous study. It tracks side effects and how often pain crises occur. The goal is to see if long-term use is safe and helps control the disease.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Sickle cell drug voxelotor tested for brain benefits in kids – study cut short
Disease control TerminatedThis study looked at whether voxelotor, a daily pill for sickle cell anemia, can improve blood flow and oxygen supply to the brain in children. The trial planned to enroll 22 participants aged 4 to 30 years with a severe form of sickle cell disease. However, the study was termina…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Sickle cell drug voxelotor tested for Long-Term safety
Disease control TerminatedThis study looked at the long-term safety of voxelotor (a daily pill) in 179 people with sickle cell disease who had already taken it in a previous trial. Participants continued taking the drug and were monitored for side effects and complications like pain crises. The trial was …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Sickle cell drug voxelotor tested for Long-Term safety – but trial ends early
Disease control TerminatedThis study looked at the long-term safety of the drug voxelotor in 162 people with sickle cell disease who had already taken it in earlier trials. Everyone received voxelotor once daily. The main goal was to track side effects. The trial was terminated early, so the full safety p…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Breathing machine may ease lung risk for kids with sickle cell
Prevention TerminatedThis study tested whether a non-invasive breathing machine (ventilation) could prevent acute chest syndrome, a serious lung complication, in children with sickle cell disease who were hospitalized for severe pain. The standard prevention is spirometry, which requires active deep …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Nasal spray could replace needles for sickle cell pain emergencies
Symptom relief TerminatedThis study tested a nasal spray containing a strong painkiller (sufentanil) for adults with sickle cell disease experiencing a painful crisis. The goal was to see if it could provide faster relief than the standard gas mixture (EMONO) before giving morphine through an IV. The tri…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
How does a blood disorder drug perform in everyday practice?
Knowledge-focused TerminatedThis study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goa…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New sickle cell drug pociredir enters early human testing
Knowledge-focused TerminatedThis early-stage study is testing a new drug called pociredir in 24 adults with sickle cell disease. Researchers want to see how the drug moves through the body and whether taking it with food changes its effects. The goal is to gather safety and dosing information, not to treat …
Phase: PHASE1 • Sponsor: Fulcrum Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC